Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has shared an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has scheduled a board meeting for 20 March 2026 to review and approve its audited consolidated financial results for the year ended 31 December 2025. The meeting may also address other business matters, signaling the upcoming release of key financial information that will be closely watched by investors and other stakeholders.
The board currently consists of a mix of executive and independent non-executive directors, reflecting standard corporate governance practices for Hong Kong–listed mainland enterprises. The confirmation of the meeting date provides clarity on the company’s financial reporting timeline, which can influence market expectations and trading activity around the announcement period.
The most recent analyst rating on (HK:0874) stock is a Hold with a HK$20.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a joint stock company based in Guangzhou, China, operating in the pharmaceutical industry. Listed in Hong Kong under H-share code 00874, it is engaged in the development, production and distribution of pharmaceutical products, serving both domestic and international healthcare markets.
Average Trading Volume: 1,262,938
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.06B
See more data about 0874 stock on TipRanks’ Stock Analysis page.